HIGHLIGHTS
- who: Stefano Cavalieri and collaborators from the Scientifico) Istituto Nazionale dei Tumori, Milan, Italy Department of and, University of Milan, Milan, Italy have published the research: An Inflammatory Signature to Predict the Clinical Benefit of First-Line Cetuximab Plus Platinum-Based Chemotherapy in Recurrent/Metastatic Head and Neck Cancer, in the Journal: (JOURNAL) of 29/07/2011
- what: The primary endpoint of the study was progression free survival (PFS) while secondary endpoints were overall survival (OS) and objective response rate (ORR). With the present analysis, the authors aimed to explore the prognostic role of an . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.